CRDL ▲ +6.3% - Cardiol Therapeutics Inc. $CRDL - Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy Cardiol Therapeutics shares rose 6.3% following the company's announcement that its Phase III MAVERIC trial has reached its enrollment target ahead of schedule and will be expanded to further evaluate CardiolRx's efficacy. The early completion of enrollment and expansion of the pivotal trial suggests progress toward potential regulatory approval of the company's lead cardiac therapy candidate. 23-SEP-2026 06:01 AM ET